Kazia Therapeutics preclinical data: paxalisib plus pembrolizumab reduces MSS/pMMR tumors
Preclinical model results show paxalisib monotherapy significantly reduced tumor burden in MSS/pMMR colorectal cancer, with pembrolizumab adding a further reduction. Paxalisib was well tolerated as monotherapy and with checkpoint inhibition.
Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further ReductionPaxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint InhibitionKazia is Preparing to Advance Paxalisi…